$Oragenics (OGEN.US)$
Oragenics, Inc. Announces Closing of Public Offering

$Oragenics (OGEN.US)$
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
Oragenics (NYSE American: OGEN) has provided an update on its drug ONP-002, intended to treat concussion, and its non-compliance with NYSE American continued listing standards. Key developments include:
1. Demonstrated stability of ONP-002 across a wide temperature range.
2. Preparation for Phase 2 clinical trials, expected to start i...

$Oragenics (OGEN.US)$
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Oragenics Inc. (NYSE American: OGEN) has announced that its lead candidate for treating concussion, ONP-002, demonstrates stability across a wide temperature range (-20°C to 104°C). This eliminates the need for cold storage, making it suitable for field use in sports and military operations. Key points:
1. ONP-002 is a new chemical entitydesigned for in...

$Oragenics (OGEN.US)$ Oragenics Inc: Onp-002 Showed No Cancer-Causing DNA Damage

$Oragenics (OGEN.US)$ As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032